XML 16 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurement - Additional Information (Detail)
9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2014
USD ($)
Sep. 30, 2014
Novozymes Biopharma DK A/S Sweden Ab
Milestone Payments
EUR (€)
Sep. 30, 2014
Novozymes Biopharma DK A/S Sweden Ab
Milestone Payments
EUR (€)
Sep. 30, 2014
Bio Flash
Minimum
USD ($)
Sep. 30, 2014
Bio Flash
Minimum
USD ($)
Sep. 30, 2014
Refine Technology, LLC
USD ($)
Jun. 02, 2014
Refine Technology, LLC
USD ($)
Jun. 02, 2014
Refine Technology, LLC
Milestone Payments
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                
Fair value of other assets $ 0              
Fair value of other liabilities 0              
Payment made 1,246,348 850,000 850,000          
Royalty payment       80,000 80,000      
Additional contingent consideration accrued           $ 1,370,000 $ 1,370,000 $ 1,400,000